ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC ArQule, Inc urinary-tract-infections-treatment.htm . and Daiichi Sankyo Co., Ltd. today announced that they can progress with a Phase 3 scientific trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in individuals with non-little cell lung cancer . In connection with this decision, the sponsor firm, Daiichi Sankyo, will file a Special Protocol Assessment with the U.S. Food and Drug Administration for a trial evaluating ARQ 197 plus erlotinib against erlotinib plus placebo. ArQule and Daiichi Sankyo signed the ARQ 197 partnership in December 2008, and in under 2 yrs, we are requesting an SPA for a Phase 3 trial with this potential first-in-course molecule.
Use of aprotinin among individuals undergoing CABG surgery does not show up prudent because safer and less expensive alternatives can be found,’ the authors conclude.. Aprotinin use associated with an increased threat of death following CABG surgery Aprotinin, a medication used for limiting blood loss in patients undergoing cardiac medical procedures, is associated with an increased risk of death during five years following a medical procedures, according to a fresh research in the February 7 problem of JAMA: The Journal of the American Medical Association. Aprotinin was initially approved for use in high-risk sufferers needing coronary artery medical procedures in the United States in 1993.